Pancreatic Cancer Drug Shows Doubled Survival in Early Results
A medication called daraxonrasib produced more than double the survival time previously seen in pancreatic cancer patients. The drug also received FDA approval for an early access program and began shipping this week.
chicago.suntimes.comA medication for pancreatic cancer produced survival results more than double those previously recorded, according to data released today. Daraxonrasib is the compound associated with the reported gains.
The same drug became available through an FDA-approved early access program. Shipments to physicians began this week. No prior treatment for pancreatic cancer has shown comparable survival improvement, the report stated.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Story details
Related Stories
jpost.comEbola Cases in Central Africa Rise from 256 to About 1,000 in Eleven Days
Suspected and confirmed Ebola cases in the Democratic Republic of the Congo and Uganda increased from 256 on 16 May to roughly 1,000 by 27 May. The World Health Organization reported about 240 deaths during the same period.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.